In silico analysis of probiotic attributes and Safety assessment of probiotic strain Bacillus coagulans BCP92 for human application

Abstract The whole genome sequence (WGS) of Bacillus coagulans BCP92, is reported, along with its genomic analysis of probiotics and safety features. Identification of bacterial strain were carried out using 16S rDNA sequencing method. Furthermore, genes related probiotic features, safety assessment (by in vitro and in silico) and genome stability were also studied WGS analysis for the possible use of the bacterial strain as a probiotic. From the BLAST analysis, bacterial strain was identified as Bacillus (Heyndrickxia) coagulans. WGS analysis indicated that the genome consists of a 34,75,658 bp and a GC-content of 46.35%. Genome mining of BCP92 had revealed that the strain is consist of coding sequences (CDS) for D-lactate dehydrogenase and L-lactate dehydrogenases, 36 genes involved in fermentation activities, 29 stress-responsive as well as many adhesions related genes. The genome also possessing genes which encoded for the synthesis of novel circular bacteriocin. Using an in-silico approach for the bacterial genome study, it was possible to determine that the Bacillus ((Heyndrickxia)) coagulans strain BCP92 contains genes that are encoded for the probiotic abilities and did not harbour genes that are risk associated, thus confirming the strain's safety and suitability as a probiotic to be used for human application.